| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
| Targets |
p65
Regaloside A targets oxidative stress pathways through its potent free radical scavenging activity. Its anti-inflammatory activity suggests modulation of inflammatory pathways. The compound's antidepressant activity indicates effects on neurotransmitter systems or neuroplasticity pathways. Its neuroprotective properties suggest interactions with pathways involved in neuronal survival and oxidative damage prevention. The compound may modulate immune responses. |
|---|---|
| ln Vitro |
In Raw 264.7 cells treated with LPS (1 μg/l; pretreatment for 15 min) Regaloside A (50 μg/mL; 2 hours) reduces COX-2 expression to 131.6 while inhibiting iNOS expression to 70.3. The ratio of p-p65/p-65 is reduced by regaloside A to 40.7[1].
In HASMCs with TNF-a (10 ng/ml; for 12 h), Regaloside A (50 μg/mL; pretreatment for 2 hours) reduces the expression of VCAM-1 to 48.6[1]. In vitro, Regaloside A shows significant DPPH radical scavenging activity of 58.0% at 160 ppm. It exhibits anti-inflammatory activity. At 50 μg/mL, Regaloside A (2 hours) inhibits the expression of inflammatory markers. The compound shows potent antioxidant, anti-inflammatory, and neuroprotective properties in cell-based assays. These activities confirm its multi-target pharmacological potential. |
| ln Vivo |
Specific in vivo data for Regaloside A are limited. Given its antidepressant activity, the compound has potential for in vivo studies in animal models of depression. Its neuroprotective properties suggest potential for in vivo studies in models of neurodegeneration. The compound's anti-inflammatory and antioxidant activities indicate potential for in vivo studies in inflammation and oxidative stress models. However, specific published in vivo protocols for this compound are not detailed.
|
| Enzyme Assay |
The antioxidant activity is assessed using DPPH radical scavenging assays. Regaloside A is dissolved in methanol or ethanol at various concentrations and mixed with a DPPH radical solution. The decrease in absorbance at 517 nm is measured after incubation, and the percentage of radical scavenging activity is calculated. Anti-inflammatory activity is assessed by measuring cytokine production in LPS-stimulated immune cells treated with the compound.
|
| Cell Assay |
For cellular studies, immune cells (e.g., macrophages, microglia) and neuronal cells are cultured in appropriate media. Cells are treated with Regaloside A at various concentrations (e.g., 1-100 μg/mL) for 24-72 hours. Cell viability is assessed using MTT or similar assays. Inflammatory cytokine levels (TNF-α, IL-6, IL-1β) are measured by ELISA. ROS levels are measured using DCFH-DA. Neuroprotective effects are assessed in cells exposed to oxidative stress or neurotoxic agents. The compound is typically dissolved in DMSO and diluted in culture media.
|
| Animal Protocol |
In vivo studies for Regaloside A would be conducted in appropriate animal models. For antidepressant studies, behavioral tests such as the forced swim test, tail suspension test, or sucrose preference test would be used. For neuroprotection studies, models of neurodegeneration (e.g., MPTP, 6-OHDA, or Aβ-induced toxicity) would be employed. For anti-inflammatory studies, models of inflammation would be used. The compound would be administered via oral gavage or intraperitoneal injection. However, specific published protocols are not available.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Regaloside A are not reported. The compound has a molecular weight of 400.38 g/mol. As a phenylpropanoid glycoside, the compound is expected to have moderate oral bioavailability. Pharmacokinetic studies would be required to determine parameters such as half-life, Cmax, and bioavailability. The compound is typically stored as a powder at -20°C and protected from light.
|
| Toxicity/Toxicokinetics |
As a natural product from lily species, which have traditional medicinal uses, Regaloside A is generally considered to have a moderate safety profile. The compound shows potent antioxidant and anti-inflammatory activities, suggesting potential benefits. However, comprehensive toxicology studies including acute, subchronic, and genotoxicity assessments have not been reported. The compound should be handled with appropriate safety precautions in laboratory settings.
|
| References | |
| Additional Infomation |
Regaloside A is reportedly found in lilies, other organisms with available data.
Regaloside A is a phenylpropanoid from lily with DPPH radical scavenging activity (58.0% at 160 ppm), anti-inflammatory activity, and antidepressant activity. It exhibits neuroprotective properties. No clinical trials exist. For research use only. |
| Molecular Formula |
C18H24O10
|
|---|---|
| Molecular Weight |
400.38
|
| Exact Mass |
400.137
|
| CAS # |
114420-66-5
|
| Related CAS # |
114420-66-5
|
| PubChem CID |
5459131
|
| Appearance |
White to off-white solid
|
| Density |
1.51g/cm3
|
| Boiling Point |
729.1ºC at 760mmHg
|
| Flash Point |
260.7ºC
|
| Vapour Pressure |
2.58E-22mmHg at 25°C
|
| Index of Refraction |
1.635
|
| LogP |
-1.1
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
28
|
| Complexity |
505
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C([H])(C([H])(C([H])(C([H])(C1([H])C([H])([H])O[H])O[H])O[H])O[H])OC([H])([H])[C@@]([H])(C([H])([H])OC(C([H])=C([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])=O)O[H]
|
| InChi Key |
PADHSFRQMFRWLS-MUWVXHEGSA-N
|
| InChi Code |
InChI=1S/C18H24O10/c19-7-13-15(23)16(24)17(25)18(28-13)27-9-12(21)8-26-14(22)6-3-10-1-4-11(20)5-2-10/h1-6,12-13,15-21,23-25H,7-9H2/b6-3+/t12-,13?,15?,16?,17?,18?/m1/s1
|
| Chemical Name |
[(2S)-2-hydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-3-(4-hydroxyphenyl)prop-2-enoate
|
| Synonyms |
Regaloside A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~249.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4976 mL | 12.4881 mL | 24.9763 mL | |
| 5 mM | 0.4995 mL | 2.4976 mL | 4.9953 mL | |
| 10 mM | 0.2498 mL | 1.2488 mL | 2.4976 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
